MindRank Pharma Founder Dr. Zhangming Niu Named to Fortune China's 40 Under 40 List
MindRank
AI Drug Developer
On August 12, 2025, Fortune magazine officially announced"Top 40 Business Elites Under 40 in China 2025"List, Founder and CEO of MindRankMr. Zhangming NiuWith pioneering achievements and exceptional commercial leadership in the AI pharmaceuticals fieldHonored to be Selected。
The "China 40 Under 40" award was initiated by Fortune Magazine in 2011, aiming to discover a new generation of outstanding innovators, value creators, and change drivers in China. It is known as the "cradle of business superstars" and is the most authoritative list of young business leaders in China. This list not only highly affirms the personal achievements of young entrepreneurs but also reflects the vitality of China's business ecosystem and the potential value for future development. The business elites on this year’s list cover multiple cutting-edge fields such as artificial intelligence, healthcare, green technology, new consumption, and intelligent manufacturing.
As the helmsman of MindRank, Mr. Zhangming Niu has successfully led his team to build an internationally leading industrial-grade one-stop AI-driven solution.Molecule Pro™, a drug design platform, has rapidly built up a portfolio of more than ten candidate drugs with high clinical and market value. Among them, MDR-001, a novel small-molecule oral GLP-1RA drug, completed Phase IIb clinical trials in May 2025, demonstrating excellent clinical data and significant commercial potential.
The deep integration of AI and pharmaceuticals has gradually moved from the concept validation stage into a new era of scaled application. During this critical period of transformation in the biopharmaceutical industry, MindRank will continue to pursue the vision of AI-driven innovation, aiming to explore and expand the efficiency and boundaries of global pharmaceutical R&D. It is committed to building an "AI + pharmaceutical" industrial ecosystem, leveraging AI technology to solve human disease challenges, and enabling patients in China and around the world to benefit sooner from medical breakthroughs brought by technological innovation.
About MindRank
MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of artificial intelligence and various cutting-edge technologies in the field of new drug research and development, thereby making more diseases treatable and restoring health to more lives.
The company owns a self-developed, internationally leading industrial-grade one-stop AI-driven innovative drug R&D platform, including the knowledge graph-based data mining platform PharmKG™, the protein dynamic simulation and structure prediction platform Molecule Dance™, and the one-stop AI drug design platform Molecule Pro™.
MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018-2020" by the authoritative European and American institution, Deep Pharma Intelligence. In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT Enterprise List as one of "China's Most Socially Impactful Startups."
MindRank's Self-Developed One-Stop AI Pharmaceutical Platform
Related Reading:
MindRank Selected as One of the Top 100 Companies to Watch in the 2023 Forbes Asia-Pacific Region
For more information, please visit the website: www.mindrank.ai
Contact: bd@mindrank.ai pr@mindrank.ai
Other: info@mindrank.ai